



Date: 29/01/2021.

To,  
The Manager  
Listing Compliance Department,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400 001.

Dear Sir/Madam,

Ref : Script Id "BAJAJHCARE", Script Code "539872".

Sub: Outcome of Board Meeting held on 29<sup>th</sup> January, 2021 & Submission of revised unaudited financial result for the Quarter ended December 31, 2020.

This is with reference to our earlier communication for "Outcome of Board Meeting held on 29<sup>th</sup> January, 2021 & Submission of financial result" dated January 29, 2021, we hereby submit a revised unaudited financial result for the Quarter ended December 31, 2020. Please note in the result already submitted today there was an oversight / typographical error in figures for previous quarter i.e. 30<sup>th</sup> Sept, 2020 w.r.t Provision for tax and Earning Per Share. We further state that, there are no change in the figures reported for third quarter as well as nine months result ended on 31<sup>st</sup> December, 2020.

We herewith again resubmit the full set of rectified result along with Limited Review Report.

Inconvenience caused to you is highly regretted.

Request you to take the above on records.

Thanking you,

Yours faithfully,

For and on behalf of Board of Directors  
of Bajaj Healthcare Limited

Mr. Aakash Keshari  
Company Secretary



Encl: a/a

**BAJAJ HEALTHCARE LIMITED**

Registered Office : 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39/A, B-39 A/1, Road No. 23, Wagle Ind. Estate, Thane(West), Thane-400 604.

• Tel. : + 91 22 6617 7400 - 499 • Fax : + 91 22 66177458 • Website : www.bajajhealth.com



**Date: 29/01/2021.**

To,  
The Manager  
Listing Compliance Department,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400 001.

Dear Sir/Madam,

**Ref : Script Id "BAJAJHCARE", Script Code "539872".**

**Sub: Outcome of Board Meeting held on 29<sup>th</sup> January, 2021 & Submission of financial result.**

We hereby inform you that at the meeting of the Board of Directors of our Company held today i.e. 29<sup>th</sup> January, 2021 has considered and approved the following:

- Unaudited Standalone Financial result for the Quarter/Nine months ended on 31<sup>st</sup> December, 2020 along Limited Review Report.
- Company has planned to enter Generic Market and have identified several products to launch in a phased manner. This will cover all major therapeutic segments like Chronic, acute and dermatological range of products. The revenue from generic market are expected to generate in first quarter of FY 2021-22.

We wish to inform you that Board Meeting commenced today at 12.30 p.m. and concluded at 02.15 PM.

We are enclosing herewith the copy of financial result.

Thanking you,

Yours faithfully,

**For and on behalf of Board of Directors  
of Bajaj Healthcare Limited**

**Mr. Aakash Keshari  
Company Secretary**



Encl: a/a

**BAJAJ HEALTHCARE LIMITED**

# Chaturvedi & Agrawal


## Chartered Accountants

**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**


**Review Report to  
The Board of Directors  
Bajaj Healthcare Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Bajaj Healthcare Limited (the "Company") for the quarter ended December 31, 2020 and year to date from April 1, 2020 to December 31, 2020 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations).
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards<sup>34</sup> "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Chaturvedi & Agrawal  
Chartered Accountants  
FRN: 101717W**



**Rasik Chaturvedi  
M. no: 039524  
UDIN: 21039524AAAAAD1508**



**Date: January 29, 2021  
Place: Thane**



**BAJAJ HEALTHCARE LIMITED**

( CIN No. : L99999MH1993PLC072892 )

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED ON 31st DECEMBER , 2020**

(Rs. In Lakhs Except for Earnings Per Share)

Particulars	Quarter Ended			Nine Month Ended		Year Ended
	31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>I. Revenue from operations</b>	17,833.44	20,663.47	9,927.23	52,480.23	29,151.18	41,000.84
<b>II. Other Income</b>	176.35	209.49	12.30	476.02	31.82	317.91
<b>III. Total Revenue (I+II)</b>	<b>18,009.79</b>	<b>20,872.96</b>	<b>9,939.53</b>	<b>52,956.25</b>	<b>29,183.00</b>	<b>41,318.74</b>
<b>IV. Expenses</b>						
(a) Cost of materials consumed (Including Other Direct Expenses)	11,802.07	15,423.60	7,671.45	37,614.06	23,062.12	32,027.10
(b) Changes in Inventories of Finished Good	314.14	191.66	-114.43	130.12	-141.03	-508.76
(c) Employee benefits expense	871.16	980.37	674.44	2,650.26	2,083.01	2,817.83
(d) Finance Costs	192.41	217.18	165.49	614.41	505.59	644.93
(d) Depreciation and amortisation expense	395.53	397.54	285.17	1,169.54	874.54	1,212.33
(e) Other expenses	440.81	836.97	358.96	1,915.08	985.12	1,519.28
<b>Total Expenses</b>	<b>14,016.12</b>	<b>18,047.32</b>	<b>9,041.08</b>	<b>44,093.48</b>	<b>27,369.35</b>	<b>37,712.73</b>
<b>V. Profit before Exceptional Items</b>	<b>3,993.67</b>	<b>2,825.64</b>	<b>898.45</b>	<b>8,862.77</b>	<b>1,813.65</b>	<b>3,606.02</b>
VI. Exceptional items	-	-	-	-	-	-
<b>VII. Profit before Extra Ordinary Items</b>	<b>3,993.67</b>	<b>2,825.64</b>	<b>898.45</b>	<b>8,862.77</b>	<b>1,813.65</b>	<b>3,606.02</b>
VIII. Extra Ordinary items	-	-	-	-	-	-
<b>VII. Profit Before Tax</b>	<b>3,993.67</b>	<b>2,825.64</b>	<b>898.45</b>	<b>8,862.77</b>	<b>1,813.65</b>	<b>3,606.02</b>
<b>VIII. Tax Expense</b>						
(a) Current tax	1,400.00	826.60	290.00	2,800.00	540.00	910.00
(b) Deferred Tax	-48.61	-12.63	-11.41	-120.34	-14.43	148.91
(c) Earlier Years	-	-	0.31	-	20.82	23.44
<b>Total Tax Expenses</b>	<b>1,351.39</b>	<b>813.97</b>	<b>278.90</b>	<b>2,679.66</b>	<b>546.39</b>	<b>1,082.35</b>
<b>IX. Profit (Loss) for the Period</b>	<b>2,642.28</b>	<b>2,011.67</b>	<b>619.55</b>	<b>6,183.11</b>	<b>1,267.26</b>	<b>2,523.67</b>
<b>X. Other comprehensive Income</b>						
(i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-25.51
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
(iii) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(iv) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
<b>Total Comprehensive Income for the Period</b>	<b>2,642.28</b>	<b>2,011.67</b>	<b>619.55</b>	<b>6,183.11</b>	<b>1,267.26</b>	<b>2,498.16</b>
<b>XI. Paid-up Equity Share Capital (Face Value Rs. 10/-)</b>	<b>1,379.92</b>	<b>1,379.92</b>	<b>1,379.92</b>	<b>1,379.92</b>	<b>1,379.92</b>	<b>1,379.92</b>
<b>XII. Other Equity excluding Revaluation Reserve</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>16,405.88</b>
<b>XIII. EPS (Not Annualised)</b>						
(a) Basic (in Rs.)	19.15	14.58	4.49	44.81	9.18	18.29
(b) Diluted (in Rs.)	19.15	14.58	4.49	44.81	9.18	18.29
<b>Dividend Declared during the Year:</b>						
Interim Dividend (Per Share)	1.25	-	-	1.25	-	-
Special Dividend (Per Share)	0.50	-	-	0.50	-	-
Cumulative Dividend Percentage	17.50%	-	-	17.50%	-	-



**Note :**

- a) The above Financial Results have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on January 29, 2021.
- b) As the Company was listed in SME segment of BSE Ltd as on 31st March 2019 and migrated to Main Board on 29th May 2019, Ind-AS is applicable from 1st April, 2020. Hence, the company has adopted Indian Accounting Standard ("Ind AS") as notified under Section 133 of the Companies Act, 2013 ("the Act") read with the Companies (Indian Accounting Standards) Rules, 2015 for first time from April 1, 2020. The above financial results have been prepared in accordance with principles as laid down in Ind AS-34 - Interim Financial Reporting.
- c) The financial results for the Quarter and Nine Month ended 31st December 2020 have been subjected to limited review by the statutory auditors of the Company. The restated comparative figures under IND -AS prepared by the Management are after exercising necessary due diligence to ensure financial results reflects true and fair view of Company's affairs in Indian Accounting Standard ("Ind AS") for Quarter and Nine Month ended 31st December 2019 and Year End figures for 31st March 2020 and are not subject to Review of the Statutory Auditors. The financial results for such period prepared under IGAAP framework were reviewed by Statutory Auditors.
- d) Reconciliation of Net profit and Reserves as reported under generally accepted accounting principles (GAAP) and as per IND AS is given below:

(Rs. in Lakhs)

Particulars (As applicable)	Profit Reconciliation			Reserves Reconciliation
	Quarter ended Dec 31, 2019	Nine Month ended Dec 31, 2019	Year Ended March 31, 2020	Year Ended March 31, 2020
Net profit after tax/ Reserve reported under previous GAAP	638.01	1289.93	2249.98	13780.70
Adjustments increasing/(decreasing) net profit/ Reserve as reported in the previous GAAP	-24.94	-30.63	360.89	-139.96
Adjustments in Deferred Tax	6.48	7.96	-87.20	38.85
Fair Value/ Revalued figure considered as Deemed Cost for Land under Property Plant and Equipment as on 01st April 2019	-	-	-	2751.79
<b>Net Profit after tax/ Reserve reported under Ind AS</b>	<b>619.55</b>	<b>1267.26</b>	<b>2523.67</b>	<b>16431.39</b>
Other Comprehensive Income / Loss (Net of Tax)	-	-	-25.51	-25.51
<b>Total Comprehensive Income (after tax)/ Reserves as reported under Ind AS</b>	<b>619.55</b>	<b>1267.26</b>	<b>2498.16</b>	<b>16405.88</b>

- e) The Statement as per IND AS - 108 on segment reporting is given as Annexure-A.
- f) Figures of previous period have been regrouped/reclassified, wherever necessary, to make them comparable and to conform with current period classification.

By Order of the Board  
For Bajaj Healthcare Limited



Mr. Sajankumar R Bajaj  
D.No.: 00225950  
Chairman and Managing Director



Date: 29th January 2021  
Place: Thane



**BAJAJ HEALTHCARE LIMITED**

( CIN No. : L99999MH1993PLC072892 )

**REPORT ON SEGMENT RESULTS FOR QUARTER ENDED ON 31st Dec, 2020**

Annexure : A

(Rs. In Lakhs)

Sr No	Particulars	Quarter Ended			Nine Month Ended		Year Ended
		31.12.2020 (Unaudited)	30.09.2020 (Unaudited)	31.12.2019 (Unaudited)	31.12.2020 (Unaudited)	31.12.2019 (Unaudited)	31.03.2020 (Audited)
A	<b>Segment Revenue ( Excluding Intersegment Revenue)</b>						
	Bulk Drugs	16601.45	17442.86	9326.81	46612.58	27282.03	38607.49
	Formulations	1231.99	3220.60	600.42	5867.65	1869.15	2464.31
	<b>Total</b>	<b>17,833.44</b>	<b>20,663.46</b>	<b>9,927.23</b>	<b>52,480.23</b>	<b>29,151.18</b>	<b>41,071.80</b>
	<b>InterSegment Revenue</b>						
	Bulk Drugs	488.54	1,043.69	503.27	2,315.69	1,491.31	2,108.98
	Formulations	7.53	29.66	20.54	40.73	62.40	86.18
	<b>Total</b>	<b>496.07</b>	<b>1,073.35</b>	<b>523.81</b>	<b>2,356.42</b>	<b>1,553.71</b>	<b>2,195.15</b>
	<b>Gross Segment Revenue ( Including Intersegment Revenue)</b>						
	Bulk Drugs	17089.99	18486.55	9830.09	48928.27	28773.34	40716.46
Formulations	1239.51	3250.26	620.96	5908.37	1931.55	2550.49	
<b>Total</b>	<b>18,329.51</b>	<b>21,736.81</b>	<b>10,451.05</b>	<b>54,836.65</b>	<b>30,704.89</b>	<b>43,266.95</b>	
B	<b>II. Segment Results</b>						
	<b>Profit / (Loss) Before Tax &amp; Finance Cost</b>						
	Bulk Drugs	4459.29	3,272.53	1,408.55	10,478.42	3,401.59	6,330.53
	Formulations	152.25	694.14	7.65	973.44	-97.23	-224.92
	<b>Total</b>	<b>4,611.54</b>	<b>3,966.67</b>	<b>1,416.20</b>	<b>11,451.86</b>	<b>3,304.36</b>	<b>6,105.61</b>
<b>Less : Interest</b>	192.41	217.18	165.49	614.41	505.59	644.93	
<b>Other Unallocable Expenditure (Net)</b>	425.46	923.85	352.26	1,974.68	985.12	1,854.66	
<b>Total Profit Before Tax</b>	<b>3,993.67</b>	<b>2,825.64</b>	<b>898.45</b>	<b>8,862.77</b>	<b>1,813.65</b>	<b>3,606.02</b>	
C	<b>I. Segment Assets</b>						
	Bulk Drugs	44,887.34	39,224.93	28,940.04	44,887.34	28,940.04	31,999.92
	Formulations	3,003.83	3,042.09	2,340.57	3,003.83	2,340.57	2,295.66
	Others	500.31	500.31	500.31	500.31	500.31	500.31
	<b>Total</b>	<b>48,391.47</b>	<b>42,767.33</b>	<b>31,780.92</b>	<b>48,391.47</b>	<b>31,780.92</b>	<b>34,795.89</b>
	<b>II. Segment Liabilities</b>						
	Bulk Drugs	23,150.11	19,438.32	13,988.31	23,150.11	13,988.31	15,489.68
	Formulations	689.87	1,101.86	532.96	689.87	532.96	584.70
	Others	824.07	900.51	704.73	824.07	704.73	434.67
	<b>Total</b>	<b>24,664.04</b>	<b>21,440.69</b>	<b>15,226.00</b>	<b>24,664.04</b>	<b>15,226.00</b>	<b>16,509.06</b>
<b>Total Capital Employed</b>	<b>23,727.43</b>	<b>21,326.64</b>	<b>16,554.92</b>	<b>23,727.43</b>	<b>16,554.92</b>	<b>18,286.83</b>	
<b>Total ( II+III)</b>	<b>48,391.47</b>	<b>42,767.33</b>	<b>31,780.92</b>	<b>48,391.47</b>	<b>31,780.92</b>	<b>34,795.89</b>	

By Order of the Board  
For Bajaj Healthcare Limited

Mr. Sajankumar R Bajaj  
D.No.: 00225950  
Chairman and Managing Director



Place : Thane  
Date: 29th January 2021